Fundraising Fox

Aviceda Therapeutics

Cambridge, US · Founded 2019 · Delaware corporation · 2 known investors

Biotech

Founders & leadership

Aviceda Therapeutics was founded in 2019 by Mohamed Genead and Michael Tolentino.

MG
Mohamed GeneadCo-founder
MT
Michael TolentinoCo-founder
DC
David CallananExecutive
TH
Tarek HassanExecutive
DK
Derek KunimotoExecutive

Board

DG
David GuyerBoard director
NT
Nancy ThomasonBoard director
CA
Christoph AdamsBoard director
EL
Erin LavelleBoard director
JW
Jay WoodsBoard director

Investors · 2

Catalio Capital Management, LPNew York
Jeito CapitalParis

Reported raises · per SEC filings

Form D private placements

$173.6M disclosed across 7 rounds · 2020–2024

▶$75MraisedJan 2025 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David CallananExecutive Officer
  • Nancy ThomasonDirector
  • Mohamed GeneadExecutive Officer, Director
  • Michael TolentinoExecutive Officer, Director
  • Christoph AdamsDirector
  • Tarek HassanExecutive Officer
  • Erin LavelleDirector
  • David GuyerDirector
  • Derek KunimotoExecutive Officer
  • Jay WoodsDirector
Offering amount
$207.5M
Amount sold
$75M
Sales commissions
$5M
Placement agents
Leerink Partners LLC
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.9MraisedMay 2024 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nancy ThomasonDirector
  • Michael TolentinoDirector
  • Christoph AdamsDirector
  • Patrick JohnsonDirector
  • Jay WoodsDirector
  • Mohamed GeneadExecutive Officer, Director
Offering amount
$27.7M
Amount sold
$18.9M
First sale
May 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.6MraisedMay 2023 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nancy ThomasonDirector
  • Patrick JohnsonDirector
  • Mohamed GeneadExecutive Officer, Director
  • Michael TolentinoDirector
  • Christoph AdamsDirector
  • Paul VukelicDirector
Offering amount
$15.6M
Amount sold
$15.6M
First sale
May 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$49.5MraisedMar 2022 · 11 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dmytro VoloshynDirector
  • Ross DarwinDirector
  • Robert KniazDirector
  • Mariusz GralewskiDirector
  • Kyrylo BigayExecutive Officer, Director
Offering amount
$79.7M
Amount sold
$49.5M
First sale
Mar 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.4MraisedMar 2022 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael TolentinoDirector
  • Derek KunimotoDirector
  • Mohamed GeneadExecutive Officer
Offering amount
$26.2M
Amount sold
$8.4M
First sale
Mar 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedAug 2021 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Mohamed GeneadExecutive Officer, Director
Offering amount
$1.9M
Amount sold
$1.9M
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedSep 2020 · 15 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Derek KunimotoExecutive Officer, Director
  • Michael TolentinoDirector
  • Mohamed A. GeneadExecutive Officer, Director
Offering amount
$4.3M
Amount sold
$4.3M
First sale
Feb 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.